Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

Original reporting
Published Nov 15, 2026, 2:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 7:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AVAH
Bullish
high confidence
Mentioned
$AVAH
Relevance
8/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$AVAHBullishHigh
01

Why it matters

The guidance raise is a fresh earnings disclosure that can shift investor expectations and drive short‑term price movement.

02

Market read

First report of higher 2026 guidance; material for traders targeting healthcare mid‑caps.

03

What to watch

Potential volatility from California rate uncertainty and the temporary nature of PDN funding may dampen long‑term upside.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Aveanna Healthcare Holdings (AVAH) operates Home Health, Hospice, Private Duty Services, and Medical Solutions, reporting Q3 results and raising 2026 guidance.

Company-level read

Ticker impact

$AVAHBullishHigh confidence
Context

Aveanna Healthcare raised its full-year 2026 revenue guidance above $2.695 B and adjusted EBITDA above $374 M, the first disclosure of these numbers.

Expected impact

upward pressure as the market prices in higher full-year guidance, with limited upside due to modest Q4 outlook

Evidence & confidence

Guidance lifts are material earnings news; investors typically bid the stock higher on improved revenue/EBITDA forecasts.

Market effects

Positive for the home‑health and hospice sector as Aveanna's growth signals demand strength.

U.S. healthcare services stocks may see modest gains following the guidance lift.

Limited; primarily affects U.S. mid‑cap healthcare investors.

Counterpoint

Flat Q4 outlook and ongoing caregiver labor shortages could weigh on the stock despite the guidance boost.

Key entities

  • Aveanna Healthcare Holdings Inc

    U.S. home‑health and hospice provider that issued the earnings call.

Related articles

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.

$AVAHHighAI 8/10

Aveanna Healthcare shares fall 6% despite third quarter beat

Aveanna Healthcare (AVAH) reported Q3 earnings of $0.23 per share, beating estimates by $0.02, with revenue of $695.5M, up 11.8% YoY. Despite this, shares fell 6.04% pre-market due to fiscal 2026 guidance that aligned with analyst expectations. The company raised its full-year revenue guidance to over $2.695B and EBITDA guidance to over $374M. All three business segments contributed to revenue growth, and net income rose to $45.5M from $14.1M YoY.